SCHEMBL548453

SCHEMBL548453

CCC(CCc1nc2cc(-c3ncccn3)ccc2[nH]1)Cc1nc2cc(-c3ncccn3)ccc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 3/20 0.40
ALDH1A1 P00352 1/20 0.34
MAPK1 P28482 1/20 0.34
DDAH1 O94760 1/20 0.34
POLB P06746 1/20 0.34
PIN1 Q13526 1/20 0.34
PDE10A Q9Y233 2/20 0.33
LMNA P02545 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALPL P05186 1/20 0.32
ALPI P09923 1/20 0.32
MAPT P10636 1/20 0.32
ALPG P10696 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL548454 0.91 AAK1 (0.51) AAK1ALDH1A1MAPK1POLBRAB9A
SCHEMBL548428 0.83 AAK1 (0.41) AAK1ALDH1A1MAPK1DDAH1POLB
SCHEMBL548445 0.82 RAB9A (0.45) ALDH1A1POLBPDE10ALMNANPC1
SCHEMBL549362 0.80 POLB (0.54) POLBKDM4EMAPTKMT2ATDP1
SCHEMBL549237 0.80 POLB (0.50) ALDH1A1POLBLMNANPC1RAB9A
SCHEMBL5308733 0.79 POLB (0.53) POLBKDM4EMAPTKMT2ATDP1
SCHEMBL548491 0.77 F10 (0.43) MAPK1POLBLMNANPC1RAB9A
SCHEMBL549128 0.76 AAK1 (0.40) AAK1MAPK1POLBLMNAKDM4E
SCHEMBL548429 0.75 AAK1 (0.49) AAK1ALDH1A1MAPK1POLBKDM4E
SCHEMBL3835038 0.74 KDM4E (0.38) AAK1ALDH1A1LMNAKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099905-A1 Combinations of drugs for the treatment of neoplasms BORISY ALEXIS 2007-05-03 US claimed
CN-1681511-A Combinations of drugs for the treatment of neoplasms COMBINATORX INC (US) 2005-10-12 CN claimed
US-20050080075-A1 Formulations, conjugates, and combinations of drugs for the treatment of neoplasms COMBINATORX, INC. 2005-04-14 US claimed
US-20050054708-A1 Combinations of drugs for the treatment of neoplasms COMINATORX, INCORPORATED 2005-03-10 US claimed
US-20040116407-A1 Combinations of drugs for the treatment of neoplasms COMBINATORX, INC. 2004-06-17 US claimed
WO-2004006849-A2 COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS COMBINATORX, INCORPORATED (US) 2004-01-22 WO claimed
EP-1891013-B1 TETRAHYDROQUINOLINE DERIVATIVES MERCK PATENT GMBH (DE) 2014-07-23 EP disclosed
US-8524732-B2 Substituted tetrahydroquinolines MERCK PATENT GMBH (DE) 2013-09-03 US disclosed
EP-2121700-B1 SUBSTITUTED TETRAHYDROQUINOLINES MERCK PATENT GMBH (DE) 2012-10-03 EP disclosed
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
US-20120130147-A1 METHODS FOR THE TREATMENT OF TUMORS WITH INDANE COMPOUNDS FINSINGER DIRK (DE) 2012-05-24 US disclosed
US-8110583-B2 treatment of tumors; 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane; maintain cells in the G2/M cell cycle MERCK PATENT GMBH (DE) 2012-02-07 US disclosed
EP-2033959-B1 Tetrahydropyranoquinoline derivatives MERCK PATENT GMBH (DE) 2011-04-27 EP disclosed
US-20050137185-A1 Combinations of drugs for the treatment of neoplasms COMBINATORX, INCORPORATED 2005-06-23 US disclosed
US-20050080075-A1 Formulations, conjugates, and combinations of drugs for the treatment of neoplasms COMBINATORX, INC. 2005-04-14 US disclosed
WO-2005027842-A2 COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS COMBINATORX, INCORPORATED (US) 2005-03-31 WO disclosed
US-20050054708-A1 Combinations of drugs for the treatment of neoplasms COMINATORX, INCORPORATED 2005-03-10 US disclosed
WO-2005011572-A2 COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS COMBINATORX, INCORPORATED (US) 2005-02-10 WO disclosed
US-20040116407-A1 Combinations of drugs for the treatment of neoplasms COMBINATORX, INC. 2004-06-17 US disclosed
WO-2004002430-A2 COMBINATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS COMBINATORX INCORPORATED (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120130147-A1 METHODS FOR THE TREATMENT OF TUMORS WITH INDANE COMPOUNDS TP53, IDH3A, IDH2 AAK1 4800/4885ALDH1A1 347/4885MAPK1 4376/4885
US-20050080075-A1 Formulations, conjugates, and combinations of drugs for the treatment of neoplasms ABCB1, SLCO1B3, SLCO1B1 AAK1 4744/4885ALDH1A1 571/4885MAPK1 4721/4885
US-20050137185-A1 Combinations of drugs for the treatment of neoplasms MKI67, DHFR, IL5 AAK1 4018/4885ALDH1A1 412/4885MAPK1 4375/4885
US-20070099905-A1 Combinations of drugs for the treatment of neoplasms VHL, NRAS, MYC AAK1 4719/4885ALDH1A1 662/4885MAPK1 4440/4885
US-20050054708-A1 Combinations of drugs for the treatment of neoplasms TYMP, DPYD, DHFR AAK1 4613/4885ALDH1A1 1543/4885MAPK1 3334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.